NAD+: Product Overview
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It carries electrons in energy production and is used up by enzymes that handle DNA repair, gene regulation and cell signaling. The body makes it from forms of vitamin B3 and from the amino acid tryptophan.
Product profile
| Attribute | Detail |
|---|---|
| Full name | Nicotinamide adenine dinucleotide (oxidized form: NAD+; reduced form: NADH) |
| Molecule type | Dinucleotide coenzyme (a pyridine nucleotide), not a peptide |
| Building blocks | Nicotinamide mononucleotide (NMN) and adenosine monophosphate (AMP), joined by a pyrophosphate bridge |
| Where it’s found | Every cell, in the cytoplasm, mitochondria and nucleus |
| Made from | Vitamin B3 forms (nicotinamide, nicotinic acid, nicotinamide riboside) and tryptophan |
| Related molecule | NADP+/NADPH, which carries one extra phosphate and supports building new molecules and antioxidant defense |
| Common forms | IV infusion, injection under the skin or into muscle, and oral precursors (NR, NMN). Oral NAD+ itself is poorly absorbed. |
| Stability | Most stable in mildly acidic solution, breaks down in alkaline conditions |
NAD+ is not a peptide
NAD+ is often sold alongside peptides in longevity and recovery clinics, and you’ll see it called an “NAD peptide.” That’s a mistake. NAD+ contains no amino acids and no peptide bonds. The label comes from clinics offering it together with peptides such as BPC-157 or GHK-Cu, not from its chemistry.
| Feature | NAD+ | Peptides |
|---|---|---|
| Chemical class | Pyridine nucleotide coenzyme | Short chains of amino acids |
| Building blocks | Nicotinamide, adenine, ribose sugars, phosphates | Amino acids |
| Main bonds | Pyrophosphate bridge and glycosidic bonds | Peptide (amide) bonds |
| Main job | Carries electrons, and is used up by regulatory enzymes | Usually binds cell receptors to send signals |
| Where it works | Inside cells: cytoplasm, mitochondria, nucleus | Mostly outside cells, at receptors on the cell surface |
| Main stability risk | Breakdown in alkaline solution | Enzyme cleavage, heat damage, clumping |
What NAD+ does
NAD+ has two quite different jobs. In energy production it’s recycled over and over. As a fuel for regulatory enzymes, it’s destroyed each time it’s used.
Job 1: carrying electrons. NAD+ picks up two electrons and a proton (together, a hydride ion) and becomes NADH:
\text{NAD}^+ + 2e^- + \text{H}^+ \rightleftharpoons \text{NADH}
This happens during glycolysis, the citric acid (TCA) cycle and fat breakdown. NADH then hands its electrons to Complex I of the mitochondrial electron transport chain, which builds the proton gradient that drives ATP production. The NAD+/NADH ratio acts as a signal of the cell’s energy state. In this role NAD+ isn’t used up. NAD(P)(H) takes part in more than 400 enzyme reactions.
Job 2: fuel for regulatory enzymes. Several enzyme families split NAD+ into nicotinamide and an ADP-ribose fragment, consuming it each time.
| Enzyme family | What it does | How it uses NAD+ |
|---|---|---|
| Sirtuins (SIRT1 to SIRT7) | Remove acetyl tags from proteins, regulating gene activity, mitochondrial function and stress responses. SIRT3 works inside mitochondria. | One NAD+ consumed per reaction |
| PARPs (mainly PARP1) | Detect DNA breaks and build poly(ADP-ribose) chains that recruit repair proteins | Heavy use. Massive DNA damage can drain NAD+ enough to kill the cell, a process called parthanatos. |
| CD38 and CD157 | Membrane enzymes that break down NAD+ and make calcium-signaling molecules | The main NAD+-degrading enzymes in many tissues |
| SARM1 | Drives the self-destruction of damaged nerve fibers | Rapidly destroys local NAD+ after nerve injury |
CD38 and aging. In mice, CD38 levels and activity rise with age, and CD38 was required for the age-related NAD+ decline. A 2020 study found that inflammatory signals from senescent cells push tissue macrophages to make more CD38. CD38 also breaks down NMN, which matters for NAD+-boosting supplements.
How the body makes NAD+
Cells keep their NAD+ supply topped up through three routes that converge on the same end product.
| Pathway | Starting material | Key steps | Importance |
|---|---|---|---|
| Salvage | Nicotinamide (NAM), released every time sirtuins, PARPs or CD38 use NAD+ | NAMPT converts NAM to NMN (the rate-limiting step), then NMNAT1 to 3 convert NMN to NAD+ | The main route in most tissues |
| Preiss-Handler | Nicotinic acid (niacin) from food | NAPRT makes NaMN, NMNAT makes NaAD, then NAD synthetase makes NAD+ | Important in the liver and kidney |
| De novo | The amino acid tryptophan | The kynurenine pathway makes quinolinic acid, which joins the Preiss-Handler route at NaMN | Smaller contribution, mainly in the liver |
The main oral precursors.
- Nicotinamide riboside (NR) enters cells through nucleoside transporters, and NRK1 and NRK2 then convert it to NMN. It’s been studied more than any other NAD+ booster in human trials.
- Nicotinamide mononucleotide (NMN) is one step from NAD+. How it gets into cells is still debated. A transporter called Slc12a8 has been proposed, but some researchers argue NMN is mostly converted to NR first and enters that way.
Both NR and NMN raise NAD+ in blood and some tissues, and they’ve been safe and well tolerated in trials so far.
NAD+ and aging: what the evidence shows
NAD+ levels clearly fall with age in rodents, but the human picture is thinner, and raising NAD+ hasn’t yet translated into proven health benefits.
In animals. NAD+ declines in many aged rodent tissues, though the size of the drop varies widely. In skeletal muscle, reported declines range from about 15% to 65%. Mice without CD38 keep higher NAD+ levels and show little or no decline with age.
In humans. Two MRI studies found brain NAD+ about 10% to 25% lower in old age than in young adulthood. Liver samples from people over 60 showed about 30% less NAD+ than samples from people under 45. A 2021 review concluded that the evidence for a universal age-related decline is limited and often confined to a single tissue. A 2025 Nature Metabolism review agreed that human data remain sparse.
Raising NAD+ in people. Oral NR and NMN reliably increase NAD+ in blood. The same 2025 review found that human trials have so far shown limited effects on health outcomes. Most trials have been small and short, with varied doses, which makes results hard to compare. No controlled trial has shown that raising NAD+ slows aging or extends human lifespan.
Routes, human evidence and IV infusion effects
| Route | How it behaves | Human evidence |
|---|---|---|
| Oral NAD+ | Largely broken down in the gut into smaller precursors before absorption | Little direct data |
| Oral NR or NMN | Absorbed and converted to NAD+ inside cells | The best-studied route. Reliably raises blood NAD+. |
| IV NAD+ | Delivered straight into the bloodstream | Small pharmacokinetic and tolerability studies only |
| Injection under the skin or into muscle | Slower absorption than IV | Very limited published data |
What happens to IV NAD+. In a 2019 pilot study, healthy men received 750 mg of NAD+ over 6 hours, about 2 mg per minute. Plasma NAD+ didn’t rise at all for the first 2 hours, meaning it was removed from the blood as fast as it went in. The breakdown products pointed to enzymes on cell surfaces splitting NAD+ outside cells. No adverse events occurred at that slow rate.
Infusion side effects. At faster, commercially typical rates, side effects are common:
- In a randomized pilot study, 500 mg of IV NR was faster to infuse and better tolerated than 500 mg of IV NAD+. Blood NAD+ was higher 3 hours after NR.
- In a 2026 real-world study of 500 mg daily for four days, people receiving NAD+ IV reported moderate to severe gastrointestinal symptoms, faster heart rate and chest pressure. Symptoms stopped when the infusion ended. NAD+ infusions averaged 97 minutes against 37 minutes for NR, because they had to be slowed.
Both studies were small and funded by an NR manufacturer, so independent data are still needed.
Why it happens. Reported symptoms include nausea, abdominal cramping, chest tightness, flushing, headache and a racing heart. They’re closely tied to infusion speed and usually ease when the drip is slowed. The exact mechanism hasn’t been established. One explanation is that rapid breakdown of NAD+ in the blood releases adenosine-related products that act on receptors in blood vessels, the gut and the heart. This hasn’t been confirmed in human studies.
Interaction to note. PARP inhibitor cancer drugs such as olaparib work partly through NAD+-dependent DNA repair pathways. Whether added NAD+ affects them hasn’t been studied, so anyone on cancer treatment should check with their oncologist.
Stability, storage and handling
NAD+ and NADH have opposite weak points, and NAD+ breaks down differently from peptides.
| Form | Stable in | Breaks down in |
|---|---|---|
| NAD+ (oxidized) | Mildly acidic solution | Neutral to alkaline solution, where the nicotinamide ring is attacked and opens |
| NADH (reduced) | Alkaline solution | Acidic solution |
Breakdown you can’t see. A degraded peptide solution may turn cloudy or form particles. NAD+ solutions stay clear as the molecule splits into nicotinamide and ADP-ribose, so appearance can’t confirm potency.
Handling basics for reconstituted NAD+:
- Keep refrigerated at 2°C to 8°C
- Protect from light
- Avoid repeated freezing and thawing
- Use promptly after mixing, following the pharmacist’s beyond-use date
- Don’t mix in the same syringe or bag with peptides or other products unless a pharmacist has confirmed compatibility. Many peptide formulations use neutral buffers, which speed NAD+ breakdown.
Sterile product quality. Injectable NAD+ must be sterile and tested for bacterial endotoxins. Endotoxin contamination can cause fever, chills and a dangerous drop in blood pressure, and it can’t be seen in the solution.
This article is for educational purposes only and does not replace medical advice. Speak with your licensed physician about NAD+ and longevity options that are available to you in the Philippines and suited to your health history.
